Clinical TrialsThe initiation of SYNCHRONY Outcomes marks the active progress of all three Phase III clinical trials for efruxifermin (EFX) in MASH patients.
Drug DevelopmentEfruxifermin is considered one of the most exciting MASH drug candidates in development, with strong potential to benefit a wider range of MASH patients.
Financial ResourcesAkero's financial resources are sufficient to fund the SYNCHRONY Histology and SYNCHRONY Real-World studies through their primary readouts, supporting the company's plans into the second half of 2027.